SCHEMBL5754960

SCHEMBL5754960

Fc1ccc(C(F)(F)F)cc1Cn1cnc(-c2ccc(Cl)c(C(F)(F)F)c2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 1/20 0.42
NOTUM Q6P988 3/20 0.40
PHF8 Q9UPP1 2/20 0.40
KDM5B Q9UGL1 3/20 0.38
KDM5A P29375 1/20 0.38
KDM4C Q9H3R0 1/20 0.38
MKNK1 Q9BUB5 1/20 0.38
MKNK2 Q9HBH9 1/20 0.38
FLT1 P17948 1/20 0.37
KDR P35968 1/20 0.37
GRIN2B Q13224 1/20 0.37
KCNH2 Q12809 2/20 0.36
CTSS P25774 1/20 0.36
CTSK P43235 1/20 0.36
NPC1 O15118 1/20 0.36
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.36
HTT P42858 1/20 0.36
RAB9A P51151 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5756087 0.76 KDM4C (0.47) PHF8KDM4CKDRGRIN2B
SCHEMBL5756587 0.75 NPC1 (0.48) PHF8KDM5BKDM4CNPC1ALDH1A1
SCHEMBL5758218 0.74 KDM5B (0.48) PHF8KDM5BKDM5AKDM4CNPC1
SCHEMBL5758470 0.72 NPC1 (0.53) PHF8KDM5BKDM4CNPC1ALDH1A1
SCHEMBL5757747 0.72 PHF8 (0.51) PHF8KDM5BKDM4CKCNH2NPC1
SCHEMBL5755514 0.68 NPC1 (0.60) PHF8KDM5BKDM5AKDM4CNPC1
SCHEMBL5758123 0.67 KDM5B (0.50) KDM5BKDM5AKDM4CKDRGRIN2B
SCHEMBL11904810 0.66 AKT1 (0.45) KDM5BKDM5AGRIN2BKCNH2
SCHEMBL14405161 0.65 CYP2E1 (0.50) KDM5BKDRCTSSCTSKNPC1
SCHEMBL5756130 0.65 NPC1 (0.43) PHF8KDM5BKDM5AKDM4CKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1194144-B1 ANTIBACTERIAL COMPOUNDS AFFINIUM PHARM INC (CA) 2006-11-02 EP claimed
US-20030149089-A1 Antibacterial compounds SMITHKLINE BEECHAM CORPORATION 2003-08-07 US claimed
JP-2003500357-A 2003-01-07 JP claimed
EP-1194144-A4 ANTIBACTERIAL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2002-08-07 EP claimed
EP-1194144-A1 ANTIBACTERIAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2002-04-10 EP claimed
WO-2000071120-A1 ANTIBACTERIAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2000-11-30 WO claimed
EP-1194144-B1 ANTIBACTERIAL COMPOUNDS AFFINIUM PHARM INC (CA) 2006-11-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149089-A1 Antibacterial compounds MRPL21, MRPS28, SPOUT1 P2RX7 4023/4885NOTUM 4134/4885PHF8 4427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.